Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Subject Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Program
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Subject Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Program
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Basic Research
You have accessRestricted Access

Vasopressin Regulates Extracellular Vesicle Uptake by Kidney Collecting Duct Cells

Wilna Oosthuyzen, Kathleen M. Scullion, Jessica R. Ivy, Emma E. Morrison, Robert W. Hunter, Philip J. Starkey Lewis, Eoghan O'Duibhir, Jonathan M. Street, Andrea Caporali, Christopher D. Gregory, Stuart J. Forbes, David J. Webb, Matthew A. Bailey and James W. Dear
JASN November 2016, 27 (11) 3345-3355; DOI: https://doi.org/10.1681/ASN.2015050568
Wilna Oosthuyzen
*British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathleen M. Scullion
*British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica R. Ivy
*British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emma E. Morrison
*British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert W. Hunter
*British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip J. Starkey Lewis
†Medical Research Council Centre for Regenerative Medicine, Scottish Centre for Regenerative Medicine, Edinburgh, United Kingdom; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eoghan O'Duibhir
†Medical Research Council Centre for Regenerative Medicine, Scottish Centre for Regenerative Medicine, Edinburgh, United Kingdom; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan M. Street
‡Renal Diagnostics and Therapeutics Unit, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Caporali
*British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher D. Gregory
§Medical Research Council Centre for Inflammation Research, University of Edinburgh, The Queen’s Medical Research Institute, Edinburgh, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stuart J. Forbes
†Medical Research Council Centre for Regenerative Medicine, Scottish Centre for Regenerative Medicine, Edinburgh, United Kingdom; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David J. Webb
*British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew A. Bailey
*British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James W. Dear
*British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Desmopressin stimulation causes ECV uptake. Fluorescent microscopy of unstimulated (left) and desmopressin-stimulated (3.16 ng/ml for 96 hours, right) mCCDC11 cells incubated with fluorescently loaded ECVs (red). Desmopressin stimulated ECV uptake into the cellular cytoplasm. Nuclei were stained with DAPI (blue), and cell membrane was stained with phalloidin (green).

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    ECV uptake by mCCDC11 cells is increased by desmopressin stimulation. (A) Flow cytometry data demonstrating no significant fluorescently loaded ECV uptake following desmopressin stimulation (3.16 ng/ml) for up to 8 hours (n=3). Fluorescent cells expressed as percentage of total cell number. (B) Flow cytometry data demonstrating ECV uptake following longer desmopressin stimulation. n=3; *P<0.05: 3.16 ng/ml desmopressin stimulation versus no stimulation. For (A) and (B) error bars represent SD. (C) Desmopressin (3.16 ng/ml for 96 hours)-stimulated mCCDC11 cells had significantly increased fluorescence after incubation with labeled ECVs. Fluorescent cells expressed as percentage of total cell number (n=5). (D) NTA analyses of fluorescently loaded ECVs in the cell culture supernatant from control and desmopressin (3.16 ng/ml for 96 hours) stimulated cells presented as the area under the concentration curve for particle sizes between 20–100 nm (n=5). Desmopressin stimulation reduced the concentration of ECVs in the supernatant. (E) Fluorescence of control and desmopressin stimulated cells (3.16 ng/ml for 96 hours) exposed to fluorescently loaded ECVs in the absence and presence of tolvaptan (10 nM). Fluorescent cells expressed as percentage of total cell number (n=5). (F) Fluorescence of control and desmopressin-stimulated cells (3.16 ng/ml for 96 hours) exposed to fluorescently loaded ECVs in the absence and presence of endothelin-1 (10 pg/ml). Fluorescent cells expressed as percentage of total cell number (n=5). (C–F) Tukey plots. Bottom and top of the box are the first and third quartiles, and the band inside is the median. The whiskers are the lowest datum still within 1.5 interquartile range of the lower quartile and the highest datum still within 1.5 interquartile range of the upper quartile. *P<0.05. AUC, area under the curve.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    ECVs deliver functional miRNA into desmopressin-stimulated mCCDC11 cells. Change in gene expression when desmopressin stimulation (3.16 ng/ml for 96 hours) is compared with unstimulated cells in the absence of ECVs, with control HUVEC-derived ECVs or with miR-503 loaded ECVs. (A) Vascular endothelial growth factor A. (B) Fibroblast growth factor 2. (C) Cyclin E-1. (D) Cell division cycle 25A. Values are expressed as the difference between control values in unstimulated cells minus control values in desmopressin-stimulated cells, with 18S as endogenous control. Negative values indicate downregulation and positive values indicate upregulation of target genes by desmopressin without or with the stated ECVs. n=9; *P<0.05. All plots are Tukey plots.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Rat primary collecting duct cells take up ECVs after desmopressin stimulation. The cells express AQP2 protein (green), as detected by fluorescent antibody labeling. Fluorescently loaded ECVs (red) enter primary cells with desmopressin (3.16 ng/ml for 2 hours) treatment. DAPI-stained nuclei are blue.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    ECV uptake by mCCDC11 cells following desmopressin stimulation is mediated by cAMP and dynamin activity. (A) Desmopressin (3.16 ng/ml for 96 hours) stimulated ECV uptake, which was decreased by PKA inhibition (H-89–25 µM) of the cAMP pathway. (B) ECV uptake was increased by cAMP stimulation through forskolin (10 µM). (C) Dynasore (150 nM) inhibition of dynamin activity decreased ECV uptake by desmopressin-stimulated cells below that of the control cells. (A–C) Fluorescent cells expressed as percentage of total cell number. n=6; *P<0.05. All plots are Tukey plots.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    ECV uptake is cell type specific. (A) NTA measurement of ECVs from different cell types before incubation with mCCDC11 cells. (B) Comparing total cell fluorescence between control and desmopressin (3.16 ng/ml for 96 hours) stimulated mCCDC11 cells after labeled ECV incubation from three cell types: mCCDC11 cells (CCD), HK2 (human proximal tubular cell line), and RG1 (murine juxtaglomerular cell line). ECVs, 1×108/ml, were added to all experiments. n=6; *P<0.05. (C) NTA analyses of cell culture supernatant incubated with different cell type derived ECVs (mCCDC11, HK2, and RG1) from control and desmopressin (3.16 ng/ml for 96 hours) stimulated cells presented as the area under the concentration curve (AUC) for particles sized between 20 and 100 nm. Desmopressin stimulation reduced the concentration of mCCDC11 and HK2 ECVs in the supernatant but not in cells incubated with RG1 ECVs (D) Polarized cells take up ECVs under desmopressin regulation. Total cell fluorescence of polarized mCCDC11 cells stimulated with desmopressin (3.16 ng/ml for 96 hours) either apically or basolaterally compared with unstimulated cells. Labeled ECVs were applied to the apical compartment of Transwell. n=3; *P<0.05. (B–D) Tukey plots. CCD, collecting duct; HK2, proximal tubule; RG1, juxtaglomerular cell derived.

  • Figure 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7.

    Vasopressin V2 receptor regulates urinary ECV excretion in mice and humans. (A) Urinary excretion of systemically adminstered ECVs in mice. Group 1: control group; urine ECV excretion following two IV injections of fluorescently loaded ECVs. Group 2: urine ECV excretion after two IV injections of labeled ECVs. Between injections, mice were treated with tolvaptan (0.3 mg/kg). n=5 per group; *P<0.05. Group 3: urine ECV excretion after two IV injections of labeled ECVs. Between injections, mice were treated with furosemide (1 mg/kg, n=4). ECV excretion expressed as percentage of the total number of injected ECVs excreted in the urine. Data expressed as a Tukey plot. (B) Twenty-four hour ECV excretion by a patient with central diabetes insipidus. Lines represent the time of desmopressin treatment (dashed line) and concentration of ECVs expressing nephron segment–specific proteins: glomerular (podocalyxin-like protein, PODX-L), proximal tubular (cubilin), and CD24 (pan-segment urinary ECV marker). ECV urine concentration measured by NTA and normalized by urinary creatinine concentration. All data are expressed as mean±SD. NTA measurements were taken in triplicate for each time point. AUC, area under the concentration curve.

  • Figure 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 8.

    Tolvaptan reduces kidney uptake of ECVs. Tissue distribution of fluorescently loaded ECVs systemically injected into mice without and with tolvaptan pretreatment. Mouse organs were harvested 1 hour after IV injection of ECVs. Red, ECVs; blue, DAPI; green, AQP2. Without tolvaptan, red signal is present in kidney tissue. With tolvaptan (0.3 mg/kg) pretreatment, the red signal is reduced. ECVs are present in liver and spleen without and with tolvaptan. Bar, 20 μm.

Additional Files

  • Figures
  • Supplemental Data

    • Supplemental Data
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 27 (11)
Journal of the American Society of Nephrology
Vol. 27, Issue 11
November 2016
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Vasopressin Regulates Extracellular Vesicle Uptake by Kidney Collecting Duct Cells
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Vasopressin Regulates Extracellular Vesicle Uptake by Kidney Collecting Duct Cells
Wilna Oosthuyzen, Kathleen M. Scullion, Jessica R. Ivy, Emma E. Morrison, Robert W. Hunter, Philip J. Starkey Lewis, Eoghan O'Duibhir, Jonathan M. Street, Andrea Caporali, Christopher D. Gregory, Stuart J. Forbes, David J. Webb, Matthew A. Bailey, James W. Dear
JASN Nov 2016, 27 (11) 3345-3355; DOI: 10.1681/ASN.2015050568

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Vasopressin Regulates Extracellular Vesicle Uptake by Kidney Collecting Duct Cells
Wilna Oosthuyzen, Kathleen M. Scullion, Jessica R. Ivy, Emma E. Morrison, Robert W. Hunter, Philip J. Starkey Lewis, Eoghan O'Duibhir, Jonathan M. Street, Andrea Caporali, Christopher D. Gregory, Stuart J. Forbes, David J. Webb, Matthew A. Bailey, James W. Dear
JASN Nov 2016, 27 (11) 3345-3355; DOI: 10.1681/ASN.2015050568
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Results
    • Discussion
    • Concise Methods
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Changes in NAD and Lipid Metabolism Drive Acidosis-Induced Acute Kidney Injury
  • Renal AAV2-Mediated Overexpression of Long Non-Coding RNA H19 Attenuates Ischemic Acute Kidney Injury Through Sponging of microRNA-30a-5p
  • NBCn1 Increases NH4+ Reabsorption Across Thick Ascending Limbs, the Capacity for Urinary NH4+ Excretion, and Early Recovery from Metabolic Acidosis
Show more Basic Research

Cited By...

  • Transfer of hepatocellular microRNA regulates cytochrome P450 2E1 in renal tubular cells
  • Mechanisms and modulation of microvesicle uptake in a model of alveolar cell communication
  • Google Scholar

Similar Articles

Related Articles

  • PubMed
  • Google Scholar

Keywords

  • exosomes
  • vasopressin
  • vesicles

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire